An Acquired CCDC6::RET Gene Fusion As Resistance Mechanism for Osimertinib in Exon 21 EGFR(L858R)-mutated Non-Small Cell Lung Cancer and Its Successful Management with Osimertinib and Selpercatinib: a Case Report and Review of Literature
JOURNAL OF CHEMOTHERAPY（2024）
Key words
Non-small cell lung cancer,EGFR-mutation,RET-fusion,Osimertinib,Selpercatinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined